



## CONTACT INFO

Marita Gomez 630-936-9105

## Glycom Announces its Unique Formulation of HMOs Significantly Improves IBS Symptoms

CHICAGO, Ill., October 30, 2019 — Global biotech company, Glycom, has announced that its unique formulation of human milk oligosaccharides (HMOs) has been shown in a clinical trial to significantly **improve IBS symptoms within four weeks**. Results of the study were presented in a plenary session at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting.

Patients were given daily doses of a proprietary blend of two types of HMOs — 2'-FL (2'-fucosyllactose) and LNnT (lacto-N-neotetraose) — contained in Holigos<sup>®</sup> (hōly-gōs) IBS, a medical food available without a prescription. Within four weeks, **77%** reported significant improvement in severity score utilizing IBS-SSS. At 12 weeks, **87%** saw clinically significant reduction in severity. Symptom reductions included:

- **59% reduction** in abdominal pain severity
- **59% decrease** in bloating
- **57% reduction** in days with abdominal pain

Additionally, patients experienced a positive effect on stool consistency based on Bristol Stool Scale:

- **37% decrease** in the number of abnormal stools from baseline in all IBS subtypes
- **4.6-fold increase** of normal stools from a baseline of 9%

The 12-week study enrolled 317 patients across the U.S. with three forms of IBS subtypes: IBS-C (constipation), IBS-D (diarrhea), and IBS-M (mix of both diarrhea and constipation).

In recent years, research has linked IBS with imbalances in gut microbiota. In particular, patients with IBS have been shown to have lower bifidobacterial counts. The HMOs — 2'-FL and LNnT— increase the bifidobacterial levels in the microbiota, improving IBS symptoms.



Holigos<sup>®</sup> IBS is a medical food sold in the U.S and Europe by Glycom. While Holigos<sup>®</sup> IBS is available without a prescription, it should be taken under medical supervision. The ingredients in Holigos<sup>®</sup> IBS have been positively reviewed by the FDA and accepted as safe. One box includes 28 single-dose packets, each containing 5 g.

The study, “Human Milk Oligosaccharides Improve All the Central Symptoms of Irritable Bowel Syndrome: A Multicenter, Open Label Trial,” was presented by Magnus Simrén, MD, PhD, professor and senior consultant at the department of internal medicine and clinical nutrition for the Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden. Dr. Simrén is also an adjunct professor of medicine at the University of North Carolina School of Medicine in Chapel Hill.

For more information about Holigos<sup>®</sup> IBS, visit: [holigos.com](http://holigos.com).

### **About Glycom**

Glycom is a global biotechnology company dedicated to the scientific, clinical and commercial development of human milk oligosaccharides (HMOs) for a broad range of health applications. Glycom, headquartered in Hørsholm, Denmark, is the world’s leading supplier of HMOs and has a U.S. facility located in Covington, La. Glycom is privately held. For more information about Glycom, visit [glycom.com](http://glycom.com).

# # #